FDA orders new eye risk warnings for Ozempic, Zepbound
Posted
Reuters (via Honolulu Star-Advertiser)
The FDA today informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.
